go-v.orgdoi

Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders

Nadia Rosencher, Paul Jacques Zufferey, Silvy Laporte, Patrick Mismetti · Clinical Investigation · 2011

  • DOI 10.4155/cli.11.39
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Apixaban is a new oral selective factor Xa inhibitor. Its efficacy and safety are being investigated in a large clinical development program across various indications in venous and arterial thrombotic disorders. A twice-daily regimen was chosen for all the studied indications of apixaban. All three Phase III studies in the prevention of venous thromboembolism after total hip or knee replacement (ADVANCE-1, -2 and -3) have been completed. On the basis of the data obtained so far, apixaban appears to be a promising new drug for the management of thrombotic diseases.

Open the resolved locator · 10.4155/cli.11.39

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 10:29 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.11.39
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.